

Neue Wege beim Multiplen Myelom

PD Dr. Maximilian Merz

Oberarzt

Medizinische Klinik I


Universitätsklinikum Leipzig

Associate Professor of Oncology


Roswell Park Comprehensive Cancer Center

Buffalo, NY, USA

Die gute Nachricht: Das MM ist HEILBAR




Multiples Myelom: trotz großer Fortschritte ein ungelöstes Problem




Slide credit: clinicaloptions.com


Multiples Myelom: trotz großer Fortschritte ein ungelöstes Problem




Der natürliche Verlauf des Multiplen Myeloms




Wie schaffen wir dennoch eine Heilung?



Immunotherapie beim Multiplen Myelom



CAR T Zellen beim Multiplen Myelom in Leipzig



CAR T Zellen beim Multiplen Myelom in Leipzig



CARTITUDE-1: Demographics and Baseline Characteristics

Characteristics	N=97
Age, median (range) years	61.0 (43–78)
Male, n (%)	57 (58.8)
Black/African American, n (%)	17 (17.5)
All plasmacytomas, ^a n (%)	19 (19.6)
Extramedullary plasmacytomas, n (%)	13 (13.4)
Bone-based plasmacytomas, n (%)	6 (6.2)
Bone marrow plasma cells ≥60%, n (%)	21 (21.9)
High-risk cytogenetic profile, n (%)	23 (23.7)
del17p	19 (19.6)
t(14;16)	2 (2.1)
t(4;14)	3 (3.1)
Tumor BCMA expression ≥50%, n (%)	57 (91.9) ^a

Characteristics	N=97
Prior lines of therapy, median (range)	6.0 (3–18)
Prior lines of therapy, n (%)	
3	17 (17.5)
4	16 (16.5)
≥5	64 (66.0)
Previous stem cell transplantation, n (%)	
Autologous	87 (89.7)
Allogeneic	8 (8.2)
Triple-class exposed, ^b n (%)	97 (100)
Penta-drug exposed, ^c n (%)	81 (83.5)
Triple-class refractory ^b	85 (87.6)
Penta-drug refractory ^c	41 (42.3)
Refractory status, n (%)	
Carfilzomib	63 (64.9)
Pomalidomide	81 (83.5)
Anti-CD38 antibody	96 (99.0)
Refractory to last line of therapy, n (%)	96 (99.0)
Years since diagnosis, median (range)	5.9 (1.6–18.2)

^aThe number of evaluable samples was 62; BCMA expression detected in all evaluable samples; ^b≥1 PI, ≥1 IMiD, and 1 anti-CD38 antibody; ^c≥2 PIs, ≥2 IMiDs, and 1 anti-CD38 antibody.

CAR T Zellen beim Multiplen Myelom in Leipzig



Was ist uns wichtig

- Die Zusammenarbeit mit ihrem behandelnden Onkologen/Onkologin
 - Äußern sie ihre Wünsche, Bedenken, Vorstellungen, Ziele
 - Fragen sie nach, wenn etwas unklar ist oder schlecht erklärt wurde
 - Kontaktieren sie uns!
- Maximilian.merz@medizin.uni-leipzig.de